Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
MarketMinute.com Stock News
November 15, 2012 at 17:08 PM EST
Tranzyme's TZP-102 Fails Trial
Tranzyme Inc. (
) reported that its stomach paralysis treatment TZP-102 failed a midstage clinical trial sending the stock price plummeting $3.02 to close at $0.95.
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial
Bots go here